MabGenesis will be attending the Animal Health, Nutrition, and Technology Innovation USA in Boston, USA, 11-13 June, 2024.
MabGenesis will be attending the upcoming Bio international Convention in San Diego, USA, 3-6 June, 2024.
MabGenesis is certified as one of the six Yokohama Chizai Mirai Enterprises 2024.
Our in-house antibody pipeline is updated. Link to the page.
MabGenesis to attend the Antibody Society of Japan Annual Meeting 2023 in Kagoshima, Japan, 1-3 December, 2023)
Our in-house antibody pipeline is updated. Link to the page.
MabGenesis will be attending the Animal Health, Nutrition and Technology Innovation Asia in Tokyo, Japan, 17-18 October, 2023.
Our in-house antibody pipeline is updated. Link to the page.
We were introduced in an article in Nikkei Biotech.
We were introduced in an article in the Nikkei.
Our in-house antibody pipeline is updated. Link to the page.
MabGenesis will participate in BIO One-on-One Partnering™ of BIO International Convention 2023 in Boston, MA, 5-8 June, 2023.
Our in-house antibody pipeline is updated. Link to the page.
We were introduced in an article in Nikkan Kogyo Shimbun.
We were introduced in an article in Nikkei Biotech.
We were introduced in an article in the Nikkei.
We were introduced in an article in Nikkei Biotech.
MabGenesis launched a naïve phage display antibody library for feline (fMOURA Library) consisting of 1010 antibody repertoire to meet therapeutic needs in fast growing pet health market.
Our company was featured in the latest Toyo Keizai (9/4/2021) Sugoi Venture 100 list.
Our company was chosen for the 2021 LIP. Yokohama Trial Subsidy.
The JHVS2020 Venture Award winner's pitch video, by MabGenesis's Yuichiro Shibazaki, is now available for public viewing (3/10~3/24) on the JHVS official website. The pitch was presented at the Japan Healthcare Venture Summit (JHVS) 2020 Symposium on February 4th.
Our CEO, Katsuhiro Shinjo, was selected as a finalist for the Innovation Spotlight Presentations at Animal Health Innovation Europe 2021 (February 22-23).
We were awarded the JHVS2020 Venture Award at the Japan Healthcare Venture Summit (JHVS) 2020, held by the Ministry of Labor in Japan. This is an award that was given to companies whose 90 second elevator pitches were deemed most impressive.
We were introduced in an article in Nikkan Kogyo Shimbun.
We were introduced in an article in Nikkei Biotech.
We received financing from Miyazaki Taiyo Capital Co., Ltd. (Headquarters: Miyazaki City, Miyazaki).
We raised 240 MM JPY during a second round of financing from Anniversaire Holdings Inc., Beyond Next Ventures Inc., Miyagin Venture Capital Inc., and SMBC Venture Capital Inc.
We have concluded a joint research agreement with Gene Techno Science Co., Ltd. (Headquarters: Chuo-ku, Tokyo, President: Masaharu Tani) to obtain an antibody that kills cancer cells…
Beyond Next Ventures Co., Ltd. underwrote a third-party allotment to raise 37.5 million yen in seed round funding.